Clinical Trial Update: Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial comparing FX006 to Kenalog-40 in post-traumatic osteoarthritis of the knee has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Osteoarthritis of the Knee

Drugs mentioned

• FX006
• KENALOG-40 (Triamcinolone acetonide)

Snippet

Sponsor: Pacira Pharmaceuticals, Inc | Conditions: Post-traumatic Osteoarthritis of the Knee | Phase 2 | Status: TERMINATED | Results posted: 2017-12-21